<clinical_study>
  <!-- This xml conforms to an XML Schema at:
    https://clinicaltrials.gov/ct2/html/images/info/public.xsd -->
  <required_header>
    <download_date>ClinicalTrials.gov processed this data on May 29, 2018</download_date>
    <link_text>Link to the current ClinicalTrials.gov record.</link_text>
    <url>https://clinicaltrials.gov/show/NCT00215254</url>
  </required_header>
  <id_info>
    <org_study_id>5639-04-3R0</org_study_id>
    <nct_id>NCT00215254</nct_id>
  </id_info>
  <brief_title>Quetiapine in Social Anxiety Disorder</brief_title>
  <official_title>A Randomized, Double-Blind, Placebo-Controlled Pilot Study of Quetiapine in Social Anxiety Disorder</official_title>
  <sponsors>
    <lead_sponsor>
      <agency>Duke University</agency>
      <agency_class>Other</agency_class>
    </lead_sponsor>
    <collaborator>
      <agency>AstraZeneca</agency>
      <agency_class>Industry</agency_class>
    </collaborator>
  </sponsors>
  <source>Duke University</source>
  <brief_summary>
    <textblock>
      The purpose of the study is to examine the effectiveness and tolerability of quetiapine for
      the treatment of social anxiety disorder (SAD). The hypothesis is that quetiapine will be
      effective and well-tolerated for patients with social anxiety disorder.
    </textblock>
  </brief_summary>
  <detailed_description>
    <textblock>
      This is an eight week, randomized, double-blind, placebo-controlled trial of quetiapine
      (100-400 mg/day)in social anxiety disorder.
    </textblock>
  </detailed_description>
  <overall_status>Completed</overall_status>
  <start_date>March 2004</start_date>
  <completion_date>February 2006</completion_date>
  <phase>Phase 2/Phase 3</phase>
  <study_type>Interventional</study_type>
  <has_expanded_access>No</has_expanded_access>
  <study_design_info>
    <allocation>Randomized</allocation>
    <intervention_model>Parallel Assignment</intervention_model>
    <primary_purpose>Treatment</primary_purpose>
    <masking>Double</masking>
  </study_design_info>
  <primary_outcome>
    <measure>Brief Social Phobia Scale (BSPS)</measure>
  </primary_outcome>
  <secondary_outcome>
    <measure>Clinical Global Impressions of Severity (CGI-S)</measure>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Clinical Global Impressions of Improvement (CGI-I)</measure>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Social Phobia Inventory (SPIN)</measure>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Hospital Anxiety and Depression Scale (HADS)</measure>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Connor Davidson Resilience Scale (CD-RISC)</measure>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Sheehan Disability Inventory (SDI)</measure>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Barnes Akathisis Scale (BAS)</measure>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Simpson-Angus Scale (SAS)</measure>
  </secondary_outcome>
  <enrollment>15</enrollment>
  <condition>Social Anxiety Disorder</condition>
  <intervention>
    <intervention_type>Drug</intervention_type>
    <intervention_name>quetiapine</intervention_name>
  </intervention>
  <eligibility>
    <criteria>
      <textblock>
        Inclusion Criteria:

          -  adult outpatients 18-65 years of age

          -  primary diagnosis of social anxiety disorder, using DSM-IV criteria

          -  minimum CGI severity score of 4 at baseline

          -  minimum BSPS score of 20 at baseline

          -  written informed consent

          -  negative serum pregnancy test for women of childbearing potential

        Exclusion Criteria:

          -  current DSM-IV diagnosis of bipolar disorder, schizophrenia or other psychotic
             disorder, or cognitive disorder due to a general medical condition

          -  any current primary anxiety disorder other than SAD or current primary depression

          -  history of substance abuse or dependence with the last 6 months

          -  suicide risk or serious suicide attempt within the last year

          -  clinically significant medical condition or laboratory abnormality

          -  women of childbearing potential who are unwilling to practice an acceptable method of
             contraception

          -  concomitant medication use for psychotropic purposes

          -  history of hypersensitivity to quetiapine
      </textblock>
    </criteria>
    <gender>All</gender>
    <minimum_age>18 Years</minimum_age>
    <maximum_age>65 Years</maximum_age>
    <healthy_volunteers>No</healthy_volunteers>
  </eligibility>
  <overall_official>
    <last_name>Jonathan Davidson, M.D.</last_name>
    <role>Principal Investigator</role>
    <affiliation>Duke University</affiliation>
  </overall_official>
  <location>
    <facility>
      <name>Duke University Medical Center</name>
      <address>
        <city>Durham</city>
        <state>North Carolina</state>
        <zip>27705</zip>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location_countries>
    <country>United States</country>
  </location_countries>
  <verification_date>March 2006</verification_date>
  <!-- For several months we've had both old and new date name tags                             -->
  <!-- Now, the old date names have been dropped.                                               -->
  <!-- The new date name replacements are:                                                      -->
  <!--     OLD (gone)                                        NEW (in use)                       -->
  <!--   lastchanged_date                         becomes   last_update_submitted               -->
  <!--   firstreceived_date                       becomes   study_first_submitted               -->
  <!--   firstreceived_results_date               becomes   results_first_submitted             -->
  <!--   firstreceived_results_disposition_date   becomes   disposition_first_submitted         -->
  <study_first_submitted>September 20, 2005</study_first_submitted>
  <study_first_submitted_qc>September 20, 2005</study_first_submitted_qc>
  <study_first_posted type="Estimate">September 22, 2005</study_first_posted>
  <last_update_submitted>December 18, 2006</last_update_submitted>
  <last_update_submitted_qc>December 18, 2006</last_update_submitted_qc>
  <last_update_posted type="Estimate">December 19, 2006</last_update_posted>
  <keyword>quetiapine</keyword>
  <keyword>social anxiety disorder</keyword>
  <keyword>antipsychotic</keyword>
  <keyword>pilot study</keyword>
  <condition_browse>
    <!-- CAUTION:  The following MeSH terms are assigned with an imperfect algorithm            -->
    <mesh_term>Disease</mesh_term>
    <mesh_term>Anxiety Disorders</mesh_term>
    <mesh_term>Phobia, Social</mesh_term>
  </condition_browse>
  <intervention_browse>
    <!-- CAUTION:  The following MeSH terms are assigned with an imperfect algorithm            -->
    <mesh_term>Quetiapine Fumarate</mesh_term>
  </intervention_browse>
  <!-- Results have not yet been posted for this study                                          -->
</clinical_study>

